A promising trial reveals pumitamig combined with chemotherapy shows high response rates, suggesting potential benefits for advanced cancer treatments.
Peter Schmid, MD, PhD
Advertisement
Articles by Peter Schmid, MD, PhD
Pumitamig shows promise as a bispecific antibody, enhancing immunotherapy effectiveness in treating triple-negative breast cancer patients.
Peter Schmid, MD, PhD, discusses the background, methods, and design of the phase 3 KEYNOTE-522 trial.
Peter Schmid, MD, PhD, discusses his key takeaways from the phase 3 KEYNOTE-522 trial and the updated findings presented at the 2024 ESMO Congress.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5